NCT02728063已完成不适用
Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- PiLeJe
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Change from baseline of intestinal permeability
研究概览
简要总结
The main objective of the study is to evaluate the effect on intestinal permeability of a supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from irritable bowel syndrome (IBS) with diarrhea predominance.
Secondary objectives of the study are to evaluate the effects of supplementation with Lactibiane Tolérance® for 4 weeks (28 days) in patients suffering from IBS with diarrhea predominance on intestinal permeability, inflammation of the digestive tract, symptoms and comfort.
Single-center study in single open arms: 30 volunteer adults suffering from Irritable Bowel Syndrome (IBS) with diarrhea predominance and matching the criteria of inclusion and non-inclusion listed below.
详细描述
single-center pilot study in single open arm:
- 2 to 6 weeks before enrollment: a screening visit (visit 0 [V0]) is carried out for verification of eligibility. time between V0 and V1 is a wash-out period with a duration decided by the physician (max 8 weeks).
- The experimental phase is composed of 2 visits (Visit 1 [V1] and Visit 2 [V2]) separated by 28 days (± 2 days) : from V1 to V2 patients are taking the product Lactibiane Tolérance®.
- V1 and V2 each include collection of stools, a blood sample, questionnaires on abdominal symptoms and quality of life, dynamic test of absorption of lactulose / mannitol to evaluate the intestinal permeability, recto-sigmoidoscopy with confocal endomicroscopy for in-vivo study of fluorescein leakage in the lamina propria and biopsies for ex-vivo measurements.
- "carmine red" test for the evaluation of intestinal transit speed is carried out the week before V1 and V2 (at least 72 hours before the visit). Questionnaires on abdominal symptoms as well as the frequency and consistency of stools are filled during the 7 days before V1 and V2 before.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age from 18 to 75;
- •With symptoms of IBS with predominant diarrhea according to the Rome III criteria;
- •For women of childbearing age: effective contraception and agreement to keep it throughout the study;
- •General and mental health compatible with participation in the study and to be followed as an outpatient in the opinion of the investigator: no clinically significant and relevant abnormality according to medical history and physical examination;
- •Agreeing to maintain their lifestyle during the study (same eating habits and physical activity);
- •Able and willing to participate in research in accordance with the protocol procedures particularly regarding consumption of the product under consideration and having signed an informed consent form dated;
- •Belonging to a social security scheme;
- •Willing to be included in the file of volunteers participating in biomedical research.
排除标准
- •Having a history of hypersensitivity to any of the ingredients of the product under consideration;
- •Having a history of hypersensitivity to fluorescein and / or red carmine (E120 food coloring);
- •With immunodeficiency or with a severe or progressive disease (cardiac, pulmonary, hepatic, renal, hematologic, neoplastic, or infectious);
- •With acute or severe chronic disease (chronic alcoholism, drug addiction) found incompatible with participation in the study by the investigator;
- •Suffering from a metabolic disorder or a chronic inflammatory digestive disease affecting the intestinal transit or absorption of nutrients such as diabetes, hyperthyroidism, celiac disease or Crohn's disease;
- •Having a medical history or current condition that, according to the investigator, may interfere with the results of the study or expose the subject to additional risk;
- •Currently under medication or food supplement treatment, according to the investigator, may interfere with the results of the study or stopped within too short before inclusion in V1 (less than a month for antibiotics, pre and probiotics, less than 14 days for antidiarrheal, steroidal anti-inflammatories, NSAIDs, aspirin, antihistamines and drugs. treatment with maximum 2 concomitant psychotropic can be tolerated only if it exists for more than 3 months before inclusion);
- •Having a lifestyle incompatible with the study by the investigator;
- •Woman during pregnancy or breastfeeding or planning to become pregnant within 2 months;
- •Planning to travel and hold during the study period or impossible to contact in case of emergency;
- •Having a psychological or linguistic inability to understand and sign the informed consent;
- •Participating in another clinical trial or exclusion period of a previous clinical trial;
- •Having received over the past 12 months, no more than 4,500 euros in payment for participation in clinical trials;
- •Under legal protection (guardianship, trusteeship) or deprived of his rights under the administrative or judicial decision.
结局指标
主要结局
Change from baseline of intestinal permeability
时间窗: at day 0 and day 28
Evolution between V1 and V2 of intestinal permeability evaluated by the lactulose-mannitol test according to the slope of urinary excretion of ingested lactulose percentage (calculated by linear regression) during the period representing the passage into the small intestine (2 to 4 hours after ingestion of lactulose-mannitol mixture).
次要结局
- Change from baseline of intestinal permeability - secondary 1(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 8(at day 0 and day 28)
- Change from the baseline of the symptomatology - secondary 12(at week 0 and week 4)
- Change from the baseline of the symptomatology - secondary 15(at week 0 and week 4)
- Change from the baseline of the symptomatology - secondary 13(at week 0 and week 4)
- Change from baseline of intestinal permeability - secondary 2(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 3(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 4(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 6(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 7(at day 0 and day 28)
- Change from the baseline of the inflammatory status - secondary 11(at day 0 and day 28)
- Change from the baseline of the symptomatology - secondary 14(at week 0 and week 4)
- Change from the baseline of the symptomatology - secondary 16(at week 0 and week 4)
- Change from baseline of intestinal permeability - secondary 5(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 9(at day 0 and day 28)
- Change from baseline of intestinal permeability - secondary 10(at day 0 and day 28)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Impact of Probiotics in Modulation of Intestinal MicrobiotaColorectal CancerNCT01895530Maria Isabel Toulson Davisson Correia33
已完成
3 期
Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's DiseaseCrohn's DiseaseNCT00944736Children's Mercy Hospital Kansas City12
已完成
2 期
Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal SymptomsIrritable Bowel SyndromeNCT01728610Danisco391
已完成
不适用
The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in ChemotherapyIntestinal PermeabilityGastrointestinal IrritationMucositisNCT03704727University of Copenhagen5
已完成
不适用
Irritable Bowel Syndrome and Lactibiane ToleranceIrritable Bowel SyndromeNCT01529359PiLeJe123